These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MiR-4728-3p could act as a marker of HER2 status.
    Author: Li H, Zhou X, Zhu J, Cheng W, Zhu W, Shu Y, Liu P.
    Journal: Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406.
    Abstract:
    BACKGROUND: MiR-4728 was recently identified to be related with HER2 in several cell lines and limited tissue samples. OBJECTIVE: To investigate whether miR-4728 could predict HER2 status in a larger cohort. METHODS: The expression of miR-4728-3p and miR-4728-5p was identified in breast cancer (BC) and gastric cancer (GC) tissues with different HER2 status using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH). An additional 22 plasma samples was investigated to explore the potential application of miR-4728 as a non-invasive biomarker in predicting HER2 status. RESULTS: MiR-4728-3p and miR-4728-5p were significantly up-regulated in HER2-positive patients compared with HER2-negative patients. Compared with the expression in adjacent normal tissues, miR-4728-3p and miR-4728-5p were both elevated in HER2-negative and HER2-positive GC tissues but only miR-4728-3p in HER2-positive BC tissues. Further analyses revealed that miR-4728-3p had greater ability than miR-4728-5p in discriminating subgroups with different intensity of HER2 staining in both BC and GC patients. In addition, miR-4728-3p but not miR-4728-5p was significantly up-regulated in plasma of BC patients with positive HER2. CONCLUSIONS: MiR-4728-3p had better ability in distinguishing patients with different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status.
    [Abstract] [Full Text] [Related] [New Search]